HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia.

Abstract
To determine whether the pharmacokinetics of 6-mercaptopurine (6-MP) would show dose dependency, we studied three different single oral doses in eight children (aged 3.6 to 15.1 years) with acute leukemia in remission. Marked interindividual differences in maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) were observed when children received the 50 mg/m2 dose. This variability decreased when the doses were increased. Six of the eight children showed a disproportionate increase in the AUC with increasing doses; the other two had a proportionate relationship between the AUC and dose. Overall mean (+/- SD) Cmax and AUC values increased disproportionately (88 +/- 123, to 326 +/- 194, to 653 +/- 344 ng/ml for Cmax, and 147 +/- 180, to 451 +/- 177, to 1291 +/- 415 ng/ml per hour for AUC, respectively) when the dose increased from 50 to 87.5 mg/m2 and then to 175 mg/m2. The results suggest that a saturable first-pass metabolism of oral 6-MP occurs with increasing oral doses in some, but not all, children. Whether and to what extent this pharmacokinetic character of oral 6-MP affects the interindividual difference in systemic exposure to the drug in children with leukemia receiving maintenance therapy require further studies.
AuthorsY Kato, T Matsushita, K Chiba, N Hijiya, T Yokoyama, T Ishizaki
JournalThe Journal of pediatrics (J Pediatr) Vol. 119 Issue 2 Pg. 311-6 (Aug 1991) ISSN: 0022-3476 [Print] United States
PMID1861221 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Mercaptopurine
Topics
  • Administration, Oral
  • Adolescent
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Female
  • Half-Life
  • Humans
  • Leukemia, Myeloid, Acute (blood, drug therapy)
  • Male
  • Mercaptopurine (administration & dosage, blood, pharmacokinetics)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (blood, drug therapy)
  • Remission Induction
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: